Key result
PC-mAb cuts post-MI infarct size ~31% vs vehicle in mice.
Why the study?
Phosphorylcholine is a pro-inflammatory epitope on apoptotic cells and PC-mAb has anti-inflammatory properties, but whether PC-mAb reduces adverse remodelling and infarct size after unreperfused MI was unknown.
Does PC-mAb treatment reduce adverse cardiac remodeling and infarct size following unreperfused transmural myocardial infarction in hypercholesterolemic APOE*3-Leiden mice?
Does PC-mAb treatment reduce adverse cardiac remodeling and infarct size following unreperfused transmural myocardial infarction in hypercholesterolemic APOE*3-Leiden mice?
Answers are grounded in this paper and cite their sources.
PC-mAb treatment limits adverse cardiac remodeling and reduces infarct size following unreperfused myocardial infarction in a hypercholesterolemic mouse model by attenuating the post-ischemic inflammatory response.
Phosphorylcholine is a pro-inflammatory epitope exposed on apoptotic cells, and phosphorylcholine monoclonal immunoglobulin (Ig)G antibodies (PC-mAb) have anti-inflammatory properties. In this study, we hypothesize that PC-mAb treatment reduces adverse cardiac remodelling and infarct size (IS) following unreperfused transmural myocardial infarction (MI). Unreperfused MI was induced by permanent ligation of the left anterior descending (LAD) coronary artery in hypercholesterolaemic APOE*3-Leiden mice. Three weeks following MI, cardiac magnetic resonance (CMR) imaging showed a reduced LV end-diastolic volume (EDV) by 21% and IS by 31% upon PC-mAb treatment as compared to the vehicle control group. In addition, the LV fibrous content was decreased by 27% and LV wall thickness was better preserved by 47% as determined by histological analysis. Two days following MI, CCL2 concentrations, assessed by use of ELISA, were decreased by 81% and circulating monocytes by 64% as assessed by use of FACS analysis. Additionally, local leucocyte infiltration determined by immunohistological analysis showed a 62% decrease after three weeks. In conclusion, the local and systemic inflammatory responses are limited by PC-mAb treatment resulting in restricted adverse cardiac remodelling and IS following unreperfused MI. This indicates that PC-mAb holds promise as a therapeutic agent following MI limiting adverse cardiac remodelling.
No takes yet. Share an insight, caveat, or question.
Pluijmert et al. (2021) studied Unreperfused transmural myocardial infarction. Phosphorylcholine monoclonal IgG antibodies (PC-mAb) vs. NaCl 0.9% w/v (vehicle) was evaluated on Infarct size (percentage of LV mass) at 3 weeks (reduced by 31%, p=0.042). PC-mAb treatment reduced infarct size by 31% and left ventricular end-diastolic volume by 21% compared to vehicle control 3 weeks after unreperfused myocardial infarction in mice.
Synapse has enriched 10 related papers. Consider them for comparative context: